TY - JOUR
T1 - Quality improvement in neurology
T2 - Child neurology quality measure set
AU - Patel, Anup D.
AU - Berg, Anne T.
AU - Billinghurst, Lori
AU - Fain, Daniel
AU - Fecske, Erin
AU - Feyma, Tim
AU - Grinspan, Zachary
AU - Houtrow, Amy
AU - Kothare, Sanjeev
AU - Kumar, Gogi
AU - Lee, Erin
AU - Monduy, Migvis
AU - Morita, Diego
AU - Szperka, Christina L.
AU - Victorio, M. Cristina
AU - Yeh, Ann
AU - Buchhalter, Jeffrey R.
N1 - Funding Information:
A. Patel receives research grants from the Pediatric Epilepsy Research Foundation, Upsher-Smith, GW Pharmaceuticals, and LivaNova. He consults for GW Pharmaceuticals and LivaNova. He is on a scientific advisory board for UCB Pharma and Supernus. A. Berg and L. Billinghurst report no disclosures relevant to the manuscript. D. Fain is a sub-investigator for the following study as of September 6, 2016: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sage-547 Injection in the Treatment of Subjects with Super-Refractory Status Epi-lepticus, Protocol number 547-SSE-301. E. Fecske and T. Feyma report no disclosures relevant to the manuscript. Z. Grinspan receives funding from the Centers for Disease Control and Prevention, the Pediatric Epilepsy Research Foundation, and the Nanette Laitman Clinical Scholars Program. A. Houtrow, S. Kothare, and G. Kumar report no disclosures relevant to the manuscript. E. Lee is an employee of the American Academy of Neurology. M. Monduy and D. Morita report no disclosures relevant to the manuscript. C. Szperka received funding from Pfizer and Miles for Migraine. M. Victorio reports no disclosures relevant to the manuscript. A. Yeh receives research funding from the NMSS, CMSC, IORM, SCN, CBMH, Chase an Idea, SickKids Foundation, Rare Diseases Foundation, MS Scientific Foundation (Canada)/MS Society, McLaughlin Centre, and Mario Battaglia Foundation. She has received unrestricted funds to run an educational symposium from the Guthy Jackson Charitable Foundation and Teva. She has served on a scientific advisory board for neurotoxicity for Juno. She serves as a relapse adjudicator for ACI. She has received honorarium for a talk from Novartis. J. Buchhalter is on the Scientific Advisory Board of the Charlie Foundation. He receives research funding from the Alberta Children’s Hospital Research Institute and the Department of Pediatrics, University of Calgary, Alberta, Canada. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
© 2017 American Academy of Neurology.
PY - 2018/1/9
Y1 - 2018/1/9
N2 - Childhood neurologic disorders, as a group, include relatively common conditions such as migraine (prevalence between 3% and 10.6% in children 3-15 years of age 1,2), transient tic disorders (TDs) (3%), 3 and specifically Tourette syndrome (TS) (0.8%), 3 and rarer disorders such as infantile spasms that may occur in only about 1,200 infants each year in the United States. These disorders account for a disproportionately higher number of emergency department visits, intensive care admissions, deaths, and higher costs when compared to other childhood illness. 4 Generally, delivery of quality care should improve outcomes and result in decreased unnecessary utilization of health services.
AB - Childhood neurologic disorders, as a group, include relatively common conditions such as migraine (prevalence between 3% and 10.6% in children 3-15 years of age 1,2), transient tic disorders (TDs) (3%), 3 and specifically Tourette syndrome (TS) (0.8%), 3 and rarer disorders such as infantile spasms that may occur in only about 1,200 infants each year in the United States. These disorders account for a disproportionately higher number of emergency department visits, intensive care admissions, deaths, and higher costs when compared to other childhood illness. 4 Generally, delivery of quality care should improve outcomes and result in decreased unnecessary utilization of health services.
UR - http://www.scopus.com/inward/record.url?scp=85044081613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044081613&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000004806
DO - 10.1212/WNL.0000000000004806
M3 - Article
C2 - 29247076
AN - SCOPUS:85044081613
VL - 90
SP - 67
EP - 73
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 2
ER -